Positron Emission Tomography — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for positron emission tomography. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
6
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Positron Emission Tomography

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Blue Earth 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating positron emission tomography. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Posluma
FLOTUFOLASTAT F-18 GALLIUM
 Blue Earth 6 42 — 2038-08-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12036290 Posluma method of use 75 2041-11-27
11413360 Posluma method of use 70 2038-11-22
12427207 Posluma formulation 55 2041-11-27
12390540 Posluma composition of matter 17 2038-08-23
12377176 Posluma composition of matter 17 2038-11-22
12357711 Posluma composition of matter 17 2038-11-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12377176 Posluma composition of matter 17 2038-11-22
12357711 Posluma composition of matter 17 2038-11-22
12390540 Posluma composition of matter 17 2038-08-23
12427207 Posluma formulation 55 2041-11-27
11413360 Posluma method of use 70 2038-11-22
12036290 Posluma method of use 75 2041-11-27

Related